OpenEvidence Raises $250 Million at $12 Billion Valuation for Medical Superintelligence

OpenEvidence has secured $250 million in a Series D funding round, propelling its valuation to a record $12 billion and cementing its status as the world’s most valuable healthcare AI company. The round was co-led by Thrive Capital and DST Global, featuring participation from elite backers including Sequoia Capital, Google Ventures, and the Mayo Clinic. Within just one year, the platform has become a staple in American medicine, utilized daily by more than 40% of physicians across 10,000 hospitals nationwide. The latest capital injection brings the total funding raised by the company to nearly $700 million over the past 12 months. This rapid financial growth mirrors the platform's explosive adoption, which supported 18 million clinical consultations from verified doctors in December 2025 alone. To put this velocity in perspective, OpenEvidence reached $100 million in annual revenue less than a year after launching its commercial operations.

Building Medical Superintelligence

The company operates as a specialized medical search engine that synthesizes answers from trusted, peer-reviewed literature rather than the general internet. The new funding will be used to invest heavily in the research and development of its multi-agent architecture, which functions like a digital expert team. A central conductor AI dynamically routes physician questions to the most relevant sub-specialist model, ensuring every answer reflects the highest level of technical expertise.

Data Moat and Clinical Trust

A key differentiator for the company is its exclusive access to high-quality data through official partnerships with organizations like the New England Journal of Medicine and the American Medical Association. By grounding its answers in the gold standard of medical knowledge, OpenEvidence avoids the hallucination risks common in general-purpose AI tools. This focus on technical excellence has allowed it to dominate a vertical where many competitors struggle to gain physician trust. CEO Daniel Nadler emphasizes that the primary mission is to provide doctors with the tools to safely deliver the best possible care. By scaling its medical superintelligence, the company aims to ensure that no life-saving guideline or study goes overlooked due to a lack of time. In 2025, over 100 million Americans were treated by doctors using the platform, highlighting its deep integration into the national healthcare infrastructure.